<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00592098</url>
  </required_header>
  <id_info>
    <org_study_id>SMR-1589 / 2PX-SP-01</org_study_id>
    <secondary_id>EUDRACT no: 2006-005447-29</secondary_id>
    <nct_id>NCT00592098</nct_id>
  </id_info>
  <brief_title>2PX (Topical Strontium Chloride Hexahydrate) in Patients With Post-Amputation Stump Pain.</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Cross-Over Study to Evaluate the Efficacy of 2PX (Topical Strontium Chloride Hexahydrate) in Patients With Persistent, Moderate-to-Severe Lower Limb Post-Amputation Stump Pain.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SantoSolve AS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SantoSolve AS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate the analgesic effect of topical strontium
      chloride in stump pain, and to prospectively determine other efficacy and safety measures of
      topical strontium chloride in stump pain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Pain Intensity (API): will be measured each evening in response to the question: 'What was your average pain intensity over the past 24 hours?' on a 100 mm VAS (0 = no pain, 100 = worst pain imaginable).</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Worst Pain Intensity (WPI)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Pain relief</measure>
    <time_frame>Weekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Sleep disturbance</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Use of rescue medication</measure>
    <time_frame>Daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Patient Global Impression of Change (PGIC)</measure>
    <time_frame>Weekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Prosthesis bothersomeness</measure>
    <time_frame>Weekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Quality of life assessment</measure>
    <time_frame>Q 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local skin irritability</measure>
    <time_frame>Q 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Q 14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Amputation Stumps</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2PX</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Strontium chloride hexahydrate</intervention_name>
    <description>Cutaneous solution, 1 ml dose per 100 sq cm of affected skin area, To be applied twice daily for 28 days.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>2PX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Cutaneous saline solution, 1 ml dose per 100 sq cm of affected skin area, To be applied twice daily for 28 days.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Lower limb amputation at least 6 months prior to inclusion

          -  Presenting with moderate-to-severe pain intensity (above 50 on 100 mm VAS) at
             screening, to be confirmed prior to randomisation as: Mean (over the 14 days run-in
             period) stump API rating above 50 on a 100 mm VAS

          -  Outpatients, aged 18 years and above

          -  Written informed consent

        Exclusion Criteria:

          -  Subjects who have received treatment with any potent opioid in the 4 weeks prior to
             study entry (i.e. an opioid assumed to cause abstinence symptoms upon abrupt
             cessation)

          -  Subjects taking any analgesic medication (except for rescue medication as defined in
             this protocol)

          -  Subjects with expressed dissatisfaction with their prosthesis comfort

          -  Pregnant or breast-feeding women

          -  Any malignant disease

          -  Subjects who have received an investigational drug or used an investigational device
             in the 30 days prior to study entry.

          -  Subjects unable to comply with the study assessments

          -  Subjects with documented or suspected alcohol or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Knut T Smerud, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Smerud Medical Research International AS, Drammensveien 41, N-0271 Oslo, Norway</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Smerud Investigator site 1</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2007</study_first_submitted>
  <study_first_submitted_qc>January 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2008</study_first_posted>
  <last_update_submitted>January 10, 2008</last_update_submitted>
  <last_update_submitted_qc>January 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2008</last_update_posted>
  <responsible_party>
    <name_title>Thorfinn Ege</name_title>
    <organization>SantoSolve AS</organization>
  </responsible_party>
  <keyword>Lower limb amputation at least 6 months prior to inclusion</keyword>
  <keyword>Presenting with moderate-to-severe pain intensity</keyword>
  <keyword>Outpatients, aged 18 years and above</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

